| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 95 | 2026 | 998 | 18.460 |
Why?
|
| Liver Cirrhosis | 97 | 2026 | 900 | 18.150 |
Why?
|
| Liver Neoplasms | 97 | 2026 | 1386 | 16.650 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 49 | 2025 | 403 | 13.700 |
Why?
|
| Hepatitis C, Chronic | 54 | 2025 | 367 | 13.440 |
Why?
|
| Hepatitis C | 41 | 2026 | 390 | 9.020 |
Why?
|
| Antiviral Agents | 50 | 2025 | 812 | 8.220 |
Why?
|
| Gastroenterology | 17 | 2026 | 220 | 7.330 |
Why?
|
| Liver Transplantation | 36 | 2025 | 1130 | 4.920 |
Why?
|
| Hepatitis B, Chronic | 16 | 2024 | 87 | 4.440 |
Why?
|
| End Stage Liver Disease | 14 | 2025 | 189 | 3.780 |
Why?
|
| Liver Diseases | 17 | 2024 | 381 | 3.620 |
Why?
|
| Early Detection of Cancer | 15 | 2026 | 418 | 3.620 |
Why?
|
| United States | 116 | 2026 | 11794 | 3.500 |
Why?
|
| Fatty Liver | 10 | 2026 | 215 | 3.430 |
Why?
|
| Veterans | 31 | 2024 | 1794 | 3.340 |
Why?
|
| Liver Diseases, Alcoholic | 7 | 2023 | 61 | 3.220 |
Why?
|
| Acute-On-Chronic Liver Failure | 7 | 2023 | 72 | 3.180 |
Why?
|
| Humans | 307 | 2026 | 131504 | 3.000 |
Why?
|
| Hepacivirus | 24 | 2023 | 273 | 2.920 |
Why?
|
| Quality Indicators, Health Care | 15 | 2026 | 237 | 2.850 |
Why?
|
| Middle Aged | 137 | 2026 | 28839 | 2.750 |
Why?
|
| United States Department of Veterans Affairs | 26 | 2024 | 713 | 2.300 |
Why?
|
| Risk Factors | 65 | 2026 | 10952 | 2.260 |
Why?
|
| Epidemics | 4 | 2021 | 58 | 2.190 |
Why?
|
| Aged | 91 | 2026 | 21238 | 2.170 |
Why?
|
| Retrospective Studies | 82 | 2025 | 17648 | 2.150 |
Why?
|
| Risk Assessment | 31 | 2026 | 3693 | 2.110 |
Why?
|
| Male | 152 | 2026 | 65158 | 2.080 |
Why?
|
| Mass Screening | 13 | 2024 | 825 | 2.040 |
Why?
|
| Healthcare Disparities | 5 | 2023 | 506 | 2.010 |
Why?
|
| Cost of Illness | 10 | 2026 | 290 | 1.980 |
Why?
|
| alpha-Fetoproteins | 18 | 2026 | 139 | 1.870 |
Why?
|
| Esophageal and Gastric Varices | 6 | 2025 | 74 | 1.860 |
Why?
|
| Female | 142 | 2026 | 71087 | 1.860 |
Why?
|
| Pancreatic Neoplasms | 8 | 2023 | 731 | 1.840 |
Why?
|
| Primary Health Care | 9 | 2025 | 785 | 1.840 |
Why?
|
| Incidence | 28 | 2026 | 3344 | 1.700 |
Why?
|
| Cohort Studies | 36 | 2025 | 5120 | 1.590 |
Why?
|
| Hepatitis B | 6 | 2023 | 174 | 1.570 |
Why?
|
| Gastrointestinal Hemorrhage | 7 | 2025 | 225 | 1.560 |
Why?
|
| Critical Pathways | 3 | 2025 | 74 | 1.390 |
Why?
|
| Prevalence | 24 | 2026 | 2692 | 1.390 |
Why?
|
| Decision Support Techniques | 6 | 2021 | 297 | 1.330 |
Why?
|
| Health Services Accessibility | 5 | 2025 | 695 | 1.310 |
Why?
|
| Quality of Health Care | 5 | 2014 | 411 | 1.300 |
Why?
|
| Adult | 71 | 2026 | 31666 | 1.260 |
Why?
|
| Health Care Costs | 7 | 2024 | 400 | 1.250 |
Why?
|
| International Classification of Diseases | 4 | 2024 | 97 | 1.250 |
Why?
|
| Ascites | 6 | 2025 | 99 | 1.240 |
Why?
|
| Cost-Benefit Analysis | 13 | 2022 | 543 | 1.170 |
Why?
|
| Adenocarcinoma | 4 | 2023 | 999 | 1.160 |
Why?
|
| Alanine Transaminase | 8 | 2024 | 156 | 1.120 |
Why?
|
| Societies, Medical | 4 | 2026 | 794 | 1.100 |
Why?
|
| Biomarkers, Tumor | 7 | 2026 | 1617 | 1.090 |
Why?
|
| Models, Theoretical | 8 | 2019 | 365 | 1.080 |
Why?
|
| Patient Admission | 2 | 2019 | 184 | 1.070 |
Why?
|
| Hospitals, Veterans | 7 | 2019 | 346 | 1.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2025 | 1409 | 1.050 |
Why?
|
| Health Services Research | 5 | 2018 | 178 | 1.030 |
Why?
|
| Acute Kidney Injury | 3 | 2025 | 685 | 1.030 |
Why?
|
| Palliative Care | 6 | 2022 | 444 | 1.020 |
Why?
|
| Proportional Hazards Models | 12 | 2024 | 1405 | 1.010 |
Why?
|
| Sustained Virologic Response | 10 | 2023 | 46 | 0.970 |
Why?
|
| Benzofurans | 4 | 2023 | 33 | 0.950 |
Why?
|
| Quinoxalines | 4 | 2023 | 39 | 0.940 |
Why?
|
| Alcohol Drinking | 5 | 2024 | 348 | 0.940 |
Why?
|
| Severity of Illness Index | 17 | 2025 | 3090 | 0.940 |
Why?
|
| Age Factors | 15 | 2024 | 2870 | 0.930 |
Why?
|
| Algorithms | 11 | 2026 | 1685 | 0.920 |
Why?
|
| Quality Improvement | 3 | 2022 | 706 | 0.920 |
Why?
|
| Hemochromatosis | 2 | 2022 | 39 | 0.920 |
Why?
|
| Prognosis | 21 | 2024 | 4951 | 0.890 |
Why?
|
| Quality of Life | 11 | 2022 | 2107 | 0.890 |
Why?
|
| Periodicals as Topic | 3 | 2017 | 180 | 0.880 |
Why?
|
| Prospective Studies | 20 | 2025 | 6485 | 0.870 |
Why?
|
| Comorbidity | 11 | 2024 | 1590 | 0.870 |
Why?
|
| Imidazoles | 4 | 2023 | 222 | 0.860 |
Why?
|
| Aged, 80 and over | 23 | 2022 | 6916 | 0.850 |
Why?
|
| Delphi Technique | 13 | 2024 | 262 | 0.850 |
Why?
|
| Waiting Lists | 8 | 2025 | 242 | 0.840 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2016 | 215 | 0.840 |
Why?
|
| Treatment Outcome | 31 | 2025 | 12936 | 0.820 |
Why?
|
| Patient Readmission | 2 | 2019 | 423 | 0.820 |
Why?
|
| Predictive Value of Tests | 13 | 2026 | 2297 | 0.810 |
Why?
|
| Interleukins | 2 | 2015 | 121 | 0.800 |
Why?
|
| Disease Progression | 10 | 2025 | 2205 | 0.760 |
Why?
|
| Proline | 2 | 2014 | 84 | 0.760 |
Why?
|
| Databases, Factual | 7 | 2022 | 1223 | 0.750 |
Why?
|
| Genotype | 12 | 2023 | 2655 | 0.750 |
Why?
|
| Oligopeptides | 2 | 2014 | 123 | 0.750 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 257 | 0.740 |
Why?
|
| Metabolic Diseases | 1 | 2023 | 137 | 0.730 |
Why?
|
| Disease Management | 2 | 2018 | 563 | 0.720 |
Why?
|
| Metabolic Syndrome | 4 | 2022 | 362 | 0.720 |
Why?
|
| Population Surveillance | 5 | 2024 | 397 | 0.710 |
Why?
|
| Referral and Consultation | 5 | 2025 | 566 | 0.710 |
Why?
|
| Veterans Health | 3 | 2018 | 171 | 0.700 |
Why?
|
| Health Equity | 1 | 2023 | 79 | 0.700 |
Why?
|
| Hypernatremia | 1 | 2021 | 32 | 0.680 |
Why?
|
| Drug Therapy, Combination | 9 | 2023 | 1168 | 0.680 |
Why?
|
| Biomedical Research | 4 | 2021 | 556 | 0.670 |
Why?
|
| Bile Duct Neoplasms | 2 | 2025 | 131 | 0.670 |
Why?
|
| Peer Review | 1 | 2020 | 36 | 0.670 |
Why?
|
| Digestive System Diseases | 2 | 2019 | 23 | 0.660 |
Why?
|
| Hyponatremia | 1 | 2021 | 74 | 0.660 |
Why?
|
| Hospitalization | 5 | 2025 | 1939 | 0.660 |
Why?
|
| Electronic Health Records | 5 | 2024 | 809 | 0.650 |
Why?
|
| Awards and Prizes | 1 | 2021 | 63 | 0.650 |
Why?
|
| Patient-Centered Care | 3 | 2022 | 228 | 0.640 |
Why?
|
| Needs Assessment | 1 | 2021 | 173 | 0.640 |
Why?
|
| Health Services Needs and Demand | 1 | 2021 | 169 | 0.630 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2020 | 90 | 0.630 |
Why?
|
| Metformin | 1 | 2021 | 167 | 0.620 |
Why?
|
| Sodium | 4 | 2021 | 281 | 0.610 |
Why?
|
| Gastrointestinal Microbiome | 7 | 2023 | 833 | 0.600 |
Why?
|
| Nutrition Surveys | 4 | 2019 | 327 | 0.590 |
Why?
|
| Coinfection | 5 | 2023 | 192 | 0.590 |
Why?
|
| Ultrasonography | 6 | 2024 | 972 | 0.580 |
Why?
|
| Reimbursement Mechanisms | 1 | 2019 | 36 | 0.580 |
Why?
|
| Mortality | 2 | 2020 | 261 | 0.580 |
Why?
|
| Global Health | 2 | 2021 | 632 | 0.580 |
Why?
|
| Awareness | 1 | 2019 | 81 | 0.580 |
Why?
|
| Obesity | 10 | 2024 | 2379 | 0.580 |
Why?
|
| Health Services Administration | 1 | 2018 | 9 | 0.570 |
Why?
|
| Patient Discharge | 2 | 2019 | 506 | 0.570 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 293 | 0.560 |
Why?
|
| Time Factors | 13 | 2021 | 6273 | 0.560 |
Why?
|
| Pancreatitis | 1 | 2019 | 140 | 0.550 |
Why?
|
| Anniversaries and Special Events | 1 | 2017 | 10 | 0.540 |
Why?
|
| Diabetes Complications | 2 | 2020 | 199 | 0.540 |
Why?
|
| Review Literature as Topic | 2 | 2019 | 52 | 0.520 |
Why?
|
| Data Mining | 1 | 2017 | 62 | 0.520 |
Why?
|
| Dyslipidemias | 2 | 2020 | 247 | 0.510 |
Why?
|
| Gastrointestinal Diseases | 2 | 2017 | 340 | 0.510 |
Why?
|
| Australia | 3 | 2021 | 176 | 0.510 |
Why?
|
| Practice Guidelines as Topic | 5 | 2022 | 1305 | 0.510 |
Why?
|
| Natural Language Processing | 1 | 2017 | 75 | 0.510 |
Why?
|
| Primary Prevention | 2 | 2016 | 175 | 0.510 |
Why?
|
| Malnutrition | 1 | 2019 | 156 | 0.510 |
Why?
|
| Machine Learning | 1 | 2020 | 375 | 0.500 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 1276 | 0.500 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 51 | 0.500 |
Why?
|
| Guideline Adherence | 4 | 2014 | 392 | 0.490 |
Why?
|
| Intestinal Mucosa | 5 | 2023 | 764 | 0.490 |
Why?
|
| Patient Compliance | 1 | 2019 | 469 | 0.490 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2011 | 302 | 0.490 |
Why?
|
| Interferons | 4 | 2025 | 136 | 0.490 |
Why?
|
| Sensitivity and Specificity | 11 | 2026 | 2143 | 0.490 |
Why?
|
| Survival Analysis | 7 | 2019 | 1522 | 0.480 |
Why?
|
| Preventive Health Services | 2 | 2013 | 58 | 0.470 |
Why?
|
| Mouth Neoplasms | 1 | 2017 | 98 | 0.470 |
Why?
|
| Consensus | 4 | 2024 | 565 | 0.470 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2015 | 5 | 0.470 |
Why?
|
| Alcohol Abstinence | 1 | 2015 | 15 | 0.470 |
Why?
|
| Trust | 1 | 2016 | 81 | 0.470 |
Why?
|
| Registries | 9 | 2025 | 1599 | 0.460 |
Why?
|
| Patient Care Team | 2 | 2017 | 557 | 0.460 |
Why?
|
| Health Status | 4 | 2016 | 387 | 0.460 |
Why?
|
| Chronic Disease | 5 | 2023 | 1233 | 0.450 |
Why?
|
| HIV Infections | 4 | 2023 | 2037 | 0.450 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2014 | 775 | 0.450 |
Why?
|
| Surveys and Questionnaires | 9 | 2025 | 4037 | 0.450 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2024 | 2116 | 0.450 |
Why?
|
| Reimbursement, Incentive | 1 | 2015 | 48 | 0.440 |
Why?
|
| Carcinoma | 1 | 2017 | 283 | 0.440 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 682 | 0.430 |
Why?
|
| Health Care Reform | 1 | 2014 | 52 | 0.430 |
Why?
|
| Self Report | 2 | 2017 | 558 | 0.420 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2014 | 20 | 0.420 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 248 | 0.420 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 651 | 0.420 |
Why?
|
| Diabetes Mellitus | 4 | 2016 | 886 | 0.420 |
Why?
|
| Colon | 4 | 2021 | 360 | 0.420 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 409 | 0.420 |
Why?
|
| Liver Failure | 2 | 2005 | 90 | 0.420 |
Why?
|
| Lactams, Macrocyclic | 4 | 2023 | 33 | 0.410 |
Why?
|
| Infectious Disease Medicine | 1 | 2013 | 13 | 0.410 |
Why?
|
| Hospital Mortality | 2 | 2017 | 1075 | 0.410 |
Why?
|
| Disease Eradication | 1 | 2014 | 40 | 0.400 |
Why?
|
| Colorectal Neoplasms | 3 | 2026 | 638 | 0.400 |
Why?
|
| Quality Assurance, Health Care | 3 | 2010 | 209 | 0.400 |
Why?
|
| Hepatic Encephalopathy | 2 | 2025 | 82 | 0.400 |
Why?
|
| Phospholipases A2, Calcium-Independent | 2 | 2024 | 19 | 0.400 |
Why?
|
| Hepatitis B virus | 6 | 2023 | 143 | 0.400 |
Why?
|
| Meta-Analysis as Topic | 2 | 2021 | 169 | 0.400 |
Why?
|
| Viremia | 6 | 2022 | 132 | 0.400 |
Why?
|
| Cyclopropanes | 4 | 2023 | 75 | 0.400 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 743 | 0.400 |
Why?
|
| Medicare | 5 | 2021 | 435 | 0.390 |
Why?
|
| Hepatitis, Alcoholic | 2 | 2025 | 29 | 0.390 |
Why?
|
| Health Planning Guidelines | 1 | 2013 | 33 | 0.390 |
Why?
|
| Young Adult | 14 | 2020 | 10092 | 0.390 |
Why?
|
| Administration, Oral | 6 | 2019 | 705 | 0.390 |
Why?
|
| Alcoholism | 1 | 2015 | 246 | 0.390 |
Why?
|
| Behavior Therapy | 1 | 2015 | 270 | 0.380 |
Why?
|
| Patient Participation | 1 | 2015 | 244 | 0.380 |
Why?
|
| Liver | 7 | 2024 | 1795 | 0.380 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 454 | 0.380 |
Why?
|
| Depressive Disorder | 1 | 2016 | 467 | 0.380 |
Why?
|
| Bibliometrics | 1 | 2012 | 39 | 0.370 |
Why?
|
| Peer Review, Research | 1 | 2012 | 45 | 0.370 |
Why?
|
| Sex Factors | 6 | 2017 | 1345 | 0.370 |
Why?
|
| Cross-Sectional Studies | 12 | 2023 | 3834 | 0.370 |
Why?
|
| Tissue and Organ Procurement | 3 | 2025 | 253 | 0.360 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 794 | 0.360 |
Why?
|
| Case-Control Studies | 6 | 2023 | 3452 | 0.360 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 3911 | 0.350 |
Why?
|
| Medical Records | 1 | 2012 | 180 | 0.350 |
Why?
|
| Sulfonamides | 4 | 2023 | 296 | 0.350 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 236 | 0.350 |
Why?
|
| Asia | 2 | 2021 | 125 | 0.340 |
Why?
|
| ROC Curve | 3 | 2021 | 615 | 0.340 |
Why?
|
| Logistic Models | 9 | 2023 | 1831 | 0.330 |
Why?
|
| Multivariate Analysis | 7 | 2016 | 1404 | 0.330 |
Why?
|
| Europe | 2 | 2021 | 372 | 0.320 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 5277 | 0.320 |
Why?
|
| Biomarkers | 7 | 2024 | 3403 | 0.320 |
Why?
|
| Risk | 4 | 2020 | 739 | 0.320 |
Why?
|
| Decision Making | 1 | 2015 | 682 | 0.320 |
Why?
|
| Emergency Service, Hospital | 4 | 2026 | 1217 | 0.320 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2026 | 142 | 0.310 |
Why?
|
| Proton Pump Inhibitors | 3 | 2009 | 278 | 0.310 |
Why?
|
| Organ Dysfunction Scores | 2 | 2020 | 52 | 0.310 |
Why?
|
| Diet | 5 | 2023 | 1119 | 0.310 |
Why?
|
| Caffeine | 2 | 2023 | 66 | 0.300 |
Why?
|
| Vitamin D Deficiency | 2 | 2025 | 85 | 0.300 |
Why?
|
| Biopsy | 4 | 2020 | 1249 | 0.300 |
Why?
|
| History, 21st Century | 2 | 2021 | 263 | 0.300 |
Why?
|
| Graft Survival | 8 | 2023 | 465 | 0.300 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 714 | 0.290 |
Why?
|
| Catheter Ablation | 1 | 2012 | 315 | 0.290 |
Why?
|
| History, 20th Century | 2 | 2021 | 366 | 0.290 |
Why?
|
| Vitamin D | 2 | 2025 | 194 | 0.290 |
Why?
|
| Tissue Donors | 6 | 2023 | 502 | 0.290 |
Why?
|
| Depression | 1 | 2017 | 1338 | 0.280 |
Why?
|
| Heart Failure | 3 | 2018 | 2306 | 0.280 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2022 | 221 | 0.280 |
Why?
|
| Texas | 6 | 2024 | 3614 | 0.280 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2022 | 144 | 0.280 |
Why?
|
| Nutrition Assessment | 2 | 2019 | 125 | 0.280 |
Why?
|
| Health Status Indicators | 1 | 2008 | 124 | 0.270 |
Why?
|
| Dyspepsia | 2 | 2022 | 108 | 0.270 |
Why?
|
| Odds Ratio | 7 | 2016 | 1235 | 0.270 |
Why?
|
| Reproducibility of Results | 7 | 2024 | 2985 | 0.270 |
Why?
|
| Patient Selection | 3 | 2020 | 723 | 0.260 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2009 | 274 | 0.260 |
Why?
|
| Bacteria | 3 | 2022 | 532 | 0.260 |
Why?
|
| Demography | 2 | 2019 | 243 | 0.260 |
Why?
|
| Publishing | 2 | 2019 | 105 | 0.260 |
Why?
|
| Protein Precursors | 2 | 2024 | 147 | 0.250 |
Why?
|
| Hepatitis B Vaccines | 3 | 2011 | 49 | 0.250 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2006 | 33 | 0.250 |
Why?
|
| Gastric Mucosa | 1 | 2009 | 489 | 0.240 |
Why?
|
| Acyltransferases | 2 | 2024 | 62 | 0.240 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 47 | 0.240 |
Why?
|
| Liver Cirrhosis, Alcoholic | 2 | 2023 | 40 | 0.240 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2025 | 338 | 0.240 |
Why?
|
| Klatskin Tumor | 1 | 2025 | 10 | 0.240 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2020 | 43 | 0.230 |
Why?
|
| Socioeconomic Factors | 3 | 2021 | 896 | 0.230 |
Why?
|
| Kidney Diseases | 1 | 2009 | 482 | 0.220 |
Why?
|
| Vitamins | 1 | 2025 | 115 | 0.220 |
Why?
|
| Evidence-Based Medicine | 3 | 2021 | 644 | 0.220 |
Why?
|
| Glucagon-Like Peptide-2 Receptor | 1 | 2024 | 13 | 0.220 |
Why?
|
| Immunosuppressive Agents | 2 | 2021 | 667 | 0.220 |
Why?
|
| Sickness Impact Profile | 1 | 2004 | 40 | 0.220 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2024 | 20 | 0.220 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 32 | 0.220 |
Why?
|
| Adenine | 1 | 2005 | 124 | 0.210 |
Why?
|
| Exercise | 3 | 2025 | 865 | 0.210 |
Why?
|
| Schools, Medical | 1 | 2025 | 115 | 0.210 |
Why?
|
| Feeding Behavior | 2 | 2023 | 724 | 0.210 |
Why?
|
| Pancreatitis, Chronic | 2 | 2015 | 82 | 0.210 |
Why?
|
| Republic of Korea | 1 | 2024 | 56 | 0.210 |
Why?
|
| Markov Chains | 3 | 2017 | 100 | 0.210 |
Why?
|
| Research Personnel | 1 | 2025 | 139 | 0.210 |
Why?
|
| Viral Load | 3 | 2012 | 406 | 0.200 |
Why?
|
| Serum Albumin | 2 | 2024 | 110 | 0.200 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 566 | 0.200 |
Why?
|
| Rectal Diseases | 1 | 2003 | 18 | 0.200 |
Why?
|
| Alcohol-Related Disorders | 1 | 2023 | 35 | 0.190 |
Why?
|
| RNA, Ribosomal, 16S | 5 | 2023 | 386 | 0.190 |
Why?
|
| Contraindications | 2 | 2013 | 77 | 0.190 |
Why?
|
| Models, Statistical | 2 | 2016 | 492 | 0.190 |
Why?
|
| Hemochromatosis Protein | 1 | 2022 | 22 | 0.190 |
Why?
|
| Trans Fatty Acids | 1 | 2022 | 13 | 0.190 |
Why?
|
| Glucocorticoids | 1 | 2025 | 350 | 0.190 |
Why?
|
| Albumins | 1 | 2022 | 92 | 0.190 |
Why?
|
| Sleep | 1 | 2025 | 373 | 0.180 |
Why?
|
| Ferritins | 1 | 2022 | 109 | 0.180 |
Why?
|
| Carbamates | 2 | 2019 | 66 | 0.180 |
Why?
|
| Survival Rate | 2 | 2017 | 2149 | 0.180 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 26 | 0.180 |
Why?
|
| Dietary Supplements | 1 | 2025 | 453 | 0.180 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2022 | 115 | 0.180 |
Why?
|
| Ribavirin | 4 | 2023 | 86 | 0.180 |
Why?
|
| Amides | 2 | 2019 | 91 | 0.170 |
Why?
|
| Clinical Coding | 1 | 2021 | 16 | 0.170 |
Why?
|
| Health Care Rationing | 1 | 2021 | 59 | 0.170 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2014 | 231 | 0.170 |
Why?
|
| Postoperative Complications | 3 | 2018 | 3113 | 0.170 |
Why?
|
| Patients | 1 | 2022 | 122 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2025 | 328 | 0.170 |
Why?
|
| Area Under Curve | 1 | 2021 | 320 | 0.170 |
Why?
|
| Hepatitis A Vaccines | 2 | 2010 | 9 | 0.170 |
Why?
|
| Tooth Loss | 1 | 2020 | 4 | 0.170 |
Why?
|
| Helicobacter pylori | 2 | 2022 | 1358 | 0.170 |
Why?
|
| Platelet Count | 4 | 2024 | 140 | 0.170 |
Why?
|
| Helicobacter Infections | 2 | 2022 | 1301 | 0.170 |
Why?
|
| Truth Disclosure | 1 | 2022 | 108 | 0.170 |
Why?
|
| Colonoscopy | 1 | 2003 | 247 | 0.170 |
Why?
|
| Cholagogues and Choleretics | 1 | 2020 | 24 | 0.160 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 470 | 0.160 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 38 | 0.160 |
Why?
|
| Periodontal Diseases | 1 | 2020 | 33 | 0.160 |
Why?
|
| Coffee | 2 | 2023 | 30 | 0.160 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2020 | 36 | 0.160 |
Why?
|
| Renal Dialysis | 2 | 2025 | 951 | 0.160 |
Why?
|
| Overweight | 1 | 2023 | 377 | 0.160 |
Why?
|
| Heterozygote | 1 | 2022 | 728 | 0.160 |
Why?
|
| Gastrointestinal Tract | 1 | 2022 | 225 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2022 | 177 | 0.150 |
Why?
|
| Learning Curve | 1 | 2020 | 58 | 0.150 |
Why?
|
| Drug Prescriptions | 2 | 2012 | 230 | 0.150 |
Why?
|
| Prothrombin | 3 | 2024 | 24 | 0.150 |
Why?
|
| Hypertension | 2 | 2020 | 1357 | 0.150 |
Why?
|
| Libya | 1 | 2019 | 3 | 0.150 |
Why?
|
| Plant Lectins | 1 | 2019 | 4 | 0.150 |
Why?
|
| Cognition Disorders | 1 | 2003 | 565 | 0.150 |
Why?
|
| Hepatomegaly | 3 | 2023 | 22 | 0.150 |
Why?
|
| Porphyria Cutanea Tarda | 1 | 2019 | 6 | 0.150 |
Why?
|
| Cryoglobulinemia | 1 | 2019 | 11 | 0.150 |
Why?
|
| Taste Perception | 1 | 2019 | 4 | 0.150 |
Why?
|
| Lichen Planus | 1 | 2019 | 9 | 0.150 |
Why?
|
| Data Warehousing | 1 | 2019 | 5 | 0.150 |
Why?
|
| Patient Acuity | 1 | 2019 | 67 | 0.150 |
Why?
|
| Prealbumin | 1 | 2019 | 27 | 0.150 |
Why?
|
| Transferrin | 1 | 2019 | 45 | 0.150 |
Why?
|
| Pakistan | 1 | 2019 | 91 | 0.150 |
Why?
|
| Telemedicine | 2 | 2023 | 519 | 0.150 |
Why?
|
| Malabsorption Syndromes | 1 | 2019 | 29 | 0.150 |
Why?
|
| Appetite | 1 | 2019 | 38 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 313 | 0.150 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 75 | 0.140 |
Why?
|
| Graft Rejection | 2 | 2020 | 560 | 0.140 |
Why?
|
| Olfactory Perception | 1 | 2019 | 36 | 0.140 |
Why?
|
| Terminal Care | 1 | 2020 | 114 | 0.140 |
Why?
|
| Medicaid | 2 | 2019 | 251 | 0.140 |
Why?
|
| Aftercare | 1 | 2019 | 154 | 0.140 |
Why?
|
| Coronary Artery Disease | 2 | 2016 | 865 | 0.140 |
Why?
|
| Liver Function Tests | 2 | 2015 | 97 | 0.140 |
Why?
|
| Chemoprevention | 1 | 2018 | 51 | 0.140 |
Why?
|
| Fluid Therapy | 1 | 2019 | 145 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2020 | 172 | 0.140 |
Why?
|
| Neoplasm Staging | 2 | 2024 | 1322 | 0.140 |
Why?
|
| Endoscopy, Digestive System | 1 | 2019 | 154 | 0.140 |
Why?
|
| Hospice Care | 1 | 2018 | 29 | 0.140 |
Why?
|
| Drug Resistance, Viral | 2 | 2023 | 56 | 0.140 |
Why?
|
| Ulcer | 3 | 2009 | 51 | 0.140 |
Why?
|
| Ethanol | 3 | 2023 | 164 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 1078 | 0.140 |
Why?
|
| Transplant Recipients | 4 | 2021 | 234 | 0.130 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2017 | 19 | 0.130 |
Why?
|
| Editorial Policies | 1 | 2017 | 49 | 0.130 |
Why?
|
| Protective Factors | 1 | 2017 | 93 | 0.130 |
Why?
|
| Propensity Score | 2 | 2016 | 265 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 131 | 0.130 |
Why?
|
| Electric Impedance | 1 | 2017 | 72 | 0.130 |
Why?
|
| Nutritional Status | 1 | 2019 | 302 | 0.130 |
Why?
|
| Journal Impact Factor | 1 | 2016 | 25 | 0.130 |
Why?
|
| Nadolol | 1 | 2016 | 12 | 0.130 |
Why?
|
| Leadership | 1 | 2019 | 241 | 0.130 |
Why?
|
| Health Personnel | 1 | 2022 | 549 | 0.130 |
Why?
|
| Insulin | 1 | 2021 | 1145 | 0.130 |
Why?
|
| Anthropometry | 1 | 2017 | 190 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 104 | 0.120 |
Why?
|
| Resuscitation | 1 | 2019 | 269 | 0.120 |
Why?
|
| Qualitative Research | 2 | 2022 | 703 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2017 | 239 | 0.120 |
Why?
|
| Recurrence | 2 | 2019 | 1478 | 0.120 |
Why?
|
| RNA, Viral | 3 | 2023 | 513 | 0.120 |
Why?
|
| Propranolol | 1 | 2016 | 111 | 0.120 |
Why?
|
| Medical History Taking | 1 | 2016 | 109 | 0.120 |
Why?
|
| Acculturation | 1 | 2016 | 61 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2019 | 828 | 0.120 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2016 | 84 | 0.120 |
Why?
|
| Inflammation | 2 | 2020 | 1490 | 0.120 |
Why?
|
| Allografts | 3 | 2021 | 209 | 0.120 |
Why?
|
| Health Services | 1 | 2016 | 68 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 1254 | 0.120 |
Why?
|
| Inappropriate Prescribing | 1 | 2015 | 40 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 366 | 0.120 |
Why?
|
| Privacy | 1 | 2015 | 27 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.110 |
Why?
|
| Mexican Americans | 1 | 2016 | 166 | 0.110 |
Why?
|
| Uridine Monophosphate | 1 | 2015 | 8 | 0.110 |
Why?
|
| Fluorenes | 1 | 2015 | 7 | 0.110 |
Why?
|
| Interferon-alpha | 4 | 2015 | 241 | 0.110 |
Why?
|
| Treatment Refusal | 1 | 2015 | 78 | 0.110 |
Why?
|
| Microbiota | 1 | 2020 | 441 | 0.110 |
Why?
|
| Health Surveys | 2 | 2007 | 262 | 0.110 |
Why?
|
| Jaundice | 1 | 2014 | 27 | 0.110 |
Why?
|
| Social Stigma | 1 | 2015 | 82 | 0.110 |
Why?
|
| Drug Costs | 1 | 2015 | 62 | 0.110 |
Why?
|
| Vietnam Conflict | 1 | 2014 | 9 | 0.110 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2023 | 59 | 0.110 |
Why?
|
| Ligation | 1 | 2014 | 136 | 0.110 |
Why?
|
| Adolescent | 7 | 2020 | 20917 | 0.110 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2014 | 4 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2017 | 494 | 0.110 |
Why?
|
| Cause of Death | 1 | 2016 | 510 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 501 | 0.100 |
Why?
|
| SEER Program | 2 | 2020 | 210 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2015 | 157 | 0.100 |
Why?
|
| Body Mass Index | 2 | 2024 | 1682 | 0.100 |
Why?
|
| Hypertension, Portal | 1 | 2014 | 79 | 0.100 |
Why?
|
| Interviews as Topic | 1 | 2015 | 440 | 0.100 |
Why?
|
| Liver Failure, Acute | 1 | 2014 | 96 | 0.100 |
Why?
|
| Appointments and Schedules | 1 | 2013 | 49 | 0.100 |
Why?
|
| Heart Rate | 1 | 2016 | 580 | 0.100 |
Why?
|
| Caregivers | 1 | 2019 | 583 | 0.100 |
Why?
|
| Lipase | 2 | 2024 | 88 | 0.100 |
Why?
|
| Drug Therapy | 1 | 2013 | 83 | 0.100 |
Why?
|
| Length of Stay | 3 | 2021 | 1393 | 0.100 |
Why?
|
| Kidney | 1 | 2019 | 1304 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1624 | 0.100 |
Why?
|
| Social Support | 1 | 2015 | 374 | 0.100 |
Why?
|
| Communication | 1 | 2016 | 530 | 0.090 |
Why?
|
| Gastric Lavage | 1 | 2011 | 2 | 0.090 |
Why?
|
| Data Collection | 1 | 2013 | 371 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2013 | 750 | 0.090 |
Why?
|
| Linear Models | 1 | 2013 | 695 | 0.090 |
Why?
|
| Smoking | 1 | 2016 | 926 | 0.090 |
Why?
|
| Vaccination | 3 | 2011 | 1040 | 0.090 |
Why?
|
| Outpatients | 1 | 2013 | 266 | 0.080 |
Why?
|
| Benchmarking | 2 | 2022 | 138 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 837 | 0.080 |
Why?
|
| Statistics as Topic | 2 | 2008 | 244 | 0.080 |
Why?
|
| Pandemics | 3 | 2023 | 1160 | 0.080 |
Why?
|
| Health Policy | 1 | 2013 | 227 | 0.080 |
Why?
|
| Health Facilities | 1 | 2010 | 68 | 0.080 |
Why?
|
| Kidney Transplantation | 2 | 2005 | 572 | 0.080 |
Why?
|
| Specialization | 1 | 2010 | 75 | 0.080 |
Why?
|
| Insurance Coverage | 1 | 2011 | 117 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 3411 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2011 | 289 | 0.070 |
Why?
|
| Stomach Ulcer | 1 | 2009 | 93 | 0.070 |
Why?
|
| Weight Loss | 2 | 2023 | 513 | 0.070 |
Why?
|
| Health Maintenance Organizations | 1 | 2008 | 18 | 0.070 |
Why?
|
| Intestinal Diseases | 1 | 2009 | 68 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2017 | 126 | 0.070 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2008 | 19 | 0.070 |
Why?
|
| Preoperative Care | 2 | 2024 | 356 | 0.070 |
Why?
|
| Inpatients | 1 | 2013 | 545 | 0.070 |
Why?
|
| Mutation | 1 | 2022 | 6177 | 0.070 |
Why?
|
| Immunization Programs | 1 | 2008 | 66 | 0.070 |
Why?
|
| Forecasting | 2 | 2020 | 361 | 0.070 |
Why?
|
| Marital Status | 1 | 2007 | 33 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2566 | 0.070 |
Why?
|
| Decision Trees | 2 | 2006 | 57 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2007 | 94 | 0.060 |
Why?
|
| Aspartate Aminotransferases | 2 | 2016 | 79 | 0.060 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2006 | 19 | 0.060 |
Why?
|
| Income | 1 | 2007 | 135 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2011 | 1313 | 0.060 |
Why?
|
| Anti-Ulcer Agents | 1 | 2006 | 114 | 0.060 |
Why?
|
| Pain | 1 | 2008 | 439 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1614 | 0.060 |
Why?
|
| Arthritis | 1 | 2006 | 85 | 0.060 |
Why?
|
| Hepatitis B e Antigens | 1 | 2005 | 14 | 0.060 |
Why?
|
| Lamivudine | 1 | 2005 | 29 | 0.060 |
Why?
|
| Organophosphonates | 1 | 2005 | 21 | 0.060 |
Why?
|
| Somatoform Disorders | 1 | 2005 | 46 | 0.060 |
Why?
|
| Emigrants and Immigrants | 2 | 2022 | 169 | 0.060 |
Why?
|
| Transaminases | 1 | 2005 | 36 | 0.060 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2024 | 5 | 0.060 |
Why?
|
| Prednisolone | 1 | 2025 | 69 | 0.060 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2024 | 37 | 0.060 |
Why?
|
| Health Resources | 1 | 2005 | 128 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2862 | 0.050 |
Why?
|
| Long-Term Care | 1 | 2004 | 70 | 0.050 |
Why?
|
| Bilirubin | 1 | 2024 | 126 | 0.050 |
Why?
|
| Probability | 1 | 2004 | 310 | 0.050 |
Why?
|
| Fast Foods | 1 | 2023 | 23 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2005 | 178 | 0.050 |
Why?
|
| Mental Health | 1 | 2007 | 382 | 0.050 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2003 | 19 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2025 | 407 | 0.050 |
Why?
|
| Policy | 1 | 2023 | 35 | 0.050 |
Why?
|
| Phospholipases | 1 | 2022 | 9 | 0.050 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2005 | 217 | 0.050 |
Why?
|
| Uvula | 1 | 2002 | 1 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2003 | 330 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 99 | 0.050 |
Why?
|
| Indians, North American | 1 | 2023 | 74 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 418 | 0.050 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2022 | 50 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2022 | 89 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2023 | 220 | 0.050 |
Why?
|
| Tenofovir | 1 | 2022 | 25 | 0.050 |
Why?
|
| Integrases | 1 | 2023 | 158 | 0.050 |
Why?
|
| Guanine | 1 | 2022 | 65 | 0.050 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2024 | 152 | 0.040 |
Why?
|
| HIV | 1 | 2023 | 179 | 0.040 |
Why?
|
| Verrucomicrobia | 1 | 2021 | 15 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2026 | 1516 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2005 | 995 | 0.040 |
Why?
|
| Radiography | 1 | 2023 | 760 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2021 | 104 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 1258 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 2 | 2005 | 942 | 0.040 |
Why?
|
| Simvastatin | 1 | 2021 | 75 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2022 | 276 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2020 | 33 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2022 | 293 | 0.040 |
Why?
|
| Oral Health | 1 | 2020 | 28 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 231 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 321 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2003 | 501 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2022 | 263 | 0.040 |
Why?
|
| Geography | 1 | 2020 | 119 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2022 | 362 | 0.040 |
Why?
|
| Germany | 1 | 2019 | 55 | 0.040 |
Why?
|
| Spain | 1 | 2019 | 62 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 23 | 0.040 |
Why?
|
| France | 1 | 2019 | 89 | 0.040 |
Why?
|
| Fibrosis | 1 | 2021 | 412 | 0.040 |
Why?
|
| Italy | 1 | 2019 | 133 | 0.040 |
Why?
|
| Health Priorities | 1 | 2019 | 41 | 0.040 |
Why?
|
| Health Behavior | 1 | 2022 | 390 | 0.040 |
Why?
|
| Contrast Media | 1 | 2022 | 490 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 254 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 285 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 87 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 492 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2021 | 278 | 0.030 |
Why?
|
| Feces | 1 | 2021 | 725 | 0.030 |
Why?
|
| Hepatitis C Antibodies | 2 | 2009 | 26 | 0.030 |
Why?
|
| Life Style | 1 | 2020 | 444 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 308 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2017 | 63 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2018 | 353 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 2016 | 41 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 372 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 306 | 0.030 |
Why?
|
| Advance Care Planning | 1 | 2016 | 41 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2016 | 69 | 0.030 |
Why?
|
| Triglycerides | 1 | 2019 | 605 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2567 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1450 | 0.030 |
Why?
|
| Paris | 1 | 2015 | 11 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1169 | 0.030 |
Why?
|
| Patient-Specific Modeling | 1 | 2015 | 11 | 0.030 |
Why?
|
| Sofosbuvir | 1 | 2015 | 20 | 0.030 |
Why?
|
| Budgets | 1 | 2015 | 16 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 685 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2015 | 35 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 1745 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 872 | 0.030 |
Why?
|
| Diet Records | 1 | 2013 | 70 | 0.020 |
Why?
|
| Rheumatic Diseases | 1 | 2014 | 78 | 0.020 |
Why?
|
| Gastrointestinal Contents | 1 | 2011 | 11 | 0.020 |
Why?
|
| Hepatitis A Antibodies | 1 | 2010 | 9 | 0.020 |
Why?
|
| Hepatitis B Antibodies | 1 | 2010 | 24 | 0.020 |
Why?
|
| Lymphoma | 1 | 2014 | 330 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2011 | 77 | 0.020 |
Why?
|
| Mass Vaccination | 1 | 2010 | 14 | 0.020 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2010 | 42 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2011 | 140 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 245 | 0.020 |
Why?
|
| Drug Users | 1 | 2009 | 9 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2014 | 505 | 0.020 |
Why?
|
| Prejudice | 1 | 2009 | 40 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1910 | 0.020 |
Why?
|
| California | 1 | 2009 | 128 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2008 | 111 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 139 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 998 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2014 | 947 | 0.020 |
Why?
|
| Models, Economic | 1 | 2006 | 57 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2006 | 102 | 0.020 |
Why?
|
| Office Visits | 1 | 2005 | 81 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 547 | 0.010 |
Why?
|
| Random Allocation | 1 | 2005 | 421 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 773 | 0.010 |
Why?
|
| Necrosis | 1 | 2002 | 194 | 0.010 |
Why?
|
| Research Design | 1 | 2005 | 722 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 34341 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 1139 | 0.010 |
Why?
|
| Child | 1 | 2020 | 26239 | 0.010 |
Why?
|
| Ischemia | 1 | 2002 | 352 | 0.010 |
Why?
|